271 related articles for article (PubMed ID: 33581876)
1. Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Kogachi S; Noureddin M
Clin Ther; 2021 Mar; 43(3):455-472. PubMed ID: 33581876
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
Zhou JH; Cai JJ; She ZG; Li HL
World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
[TBL] [Abstract][Full Text] [Related]
3. Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications.
Hydes T; Brown E; Hamid A; Bateman AC; Cuthbertson DJ
Clin Ther; 2021 Sep; 43(9):1505-1522. PubMed ID: 34400007
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials.
Caussy C; Reeder SB; Sirlin CB; Loomba R
Hepatology; 2018 Aug; 68(2):763-772. PubMed ID: 29356032
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Castera L; Friedrich-Rust M; Loomba R
Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.
Tsai E; Lee TP
Clin Liver Dis; 2018 Feb; 22(1):73-92. PubMed ID: 29128062
[TBL] [Abstract][Full Text] [Related]
7. Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).
Drescher HK; Weiskirchen S; Weiskirchen R
Cells; 2019 Aug; 8(8):. PubMed ID: 31394730
[TBL] [Abstract][Full Text] [Related]
8. Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis.
Shi YW; Fan JG
Clin Mol Hepatol; 2023 Feb; 29(Suppl):S228-S243. PubMed ID: 36521452
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and Monitoring of Nonalcoholic Steatohepatitis: Current State and Future Directions.
Kadi D; Loomba R; Bashir MR
Radiology; 2024 Jan; 310(1):e222695. PubMed ID: 38226882
[TBL] [Abstract][Full Text] [Related]
11. Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease.
Lin CH; Kohli R
Curr Gastroenterol Rep; 2020 Aug; 22(10):52. PubMed ID: 32814993
[TBL] [Abstract][Full Text] [Related]
12. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments.
Ahn SB
Clin Mol Hepatol; 2023 Feb; 29(Suppl):S150-S156. PubMed ID: 36696960
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis.
Zhang JZ; Cai JJ; Yu Y; She ZG; Li H
Gene Expr; 2019 Nov; 19(3):187-198. PubMed ID: 31010457
[TBL] [Abstract][Full Text] [Related]
15. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers.
Kamada Y; Ono M; Hyogo H; Fujii H; Sumida Y; Mori K; Tanaka S; Yamada M; Akita M; Mizutani K; Fujii H; Yamamoto A; Takamatsu S; Yoshida Y; Itoh Y; Kawada N; Chayama K; Saibara T; Takehara T; Miyoshi E
Hepatology; 2015 Nov; 62(5):1433-43. PubMed ID: 26199205
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive Diagnosis of NAFLD and NASH.
Piazzolla VA; Mangia A
Cells; 2020 Apr; 9(4):. PubMed ID: 32316690
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease.
Lee DH
Endocrinol Metab (Seoul); 2020 Jun; 35(2):243-259. PubMed ID: 32615709
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?
Alkhouri N; Feldstein AE
Metabolism; 2016 Aug; 65(8):1087-95. PubMed ID: 26972222
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive biomarkers in pediatric nonalcoholic fatty liver disease.
Jayasekera D; Hartmann P
World J Hepatol; 2023 May; 15(5):609-640. PubMed ID: 37305367
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine.
Noureddin M; Mato JM; Lu SC
Exp Biol Med (Maywood); 2015 Jun; 240(6):809-20. PubMed ID: 25873078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
